Trial Profile
Phase I/II Study of PTX-9908 Injection as an Inhibitor of Cancer Progression in Patients With Non-resectable Hepatocellular Carcinoma Following Transarterial Chemoembolization Treatment
Status:
Recruiting
Phase of Trial:
Phase I/II
Latest Information Update: 30 Jun 2023
Price :
$35
*
At a glance
- Drugs PTX 9908 (Primary)
- Indications Liver cancer
- Focus Adverse reactions
- Sponsors TCM Biotech International
- 25 Jun 2023 Planned End Date changed from 30 Dec 2023 to 30 Dec 2024.
- 25 Jun 2023 Planned primary completion date changed from 30 Aug 2023 to 30 Aug 2024.
- 25 Apr 2022 Planned End Date changed from 30 Dec 2021 to 30 Dec 2023.